Latanoprostene bunod

In today's world, Latanoprostene bunod remains a topic of constant interest and debate. Over time, its relevance has increased and has impacted different sectors of society. From the personal level to the professional level, Latanoprostene bunod has proven to be a crucial point that cannot be ignored. Its influence has spread to all corners of the world, affecting people of all ages, cultures and conditions. In this article, we will explore in detail the various facets of Latanoprostene bunod and how it has shaped and continues to shape our reality.

Latanoprostene bunod
Clinical data
Trade namesVyzulta
Other namesBOL-303259-X
AHFS/Drugs.comMonograph
License data
Drug classProstaglandin analog
ATC code
Legal status
Legal status
Identifiers
  • 4-Nitrooxybutyl (Z)-7-cyclopentyl]hept-5-enoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.251.571 Edit this at Wikidata
Chemical and physical data
FormulaC27H41NO8
Molar mass507.624 g·mol−1
3D model (JSmol)
  • C1(((1O)C/C=C\CCCC(=O)OCCCCO(=O))CC(CCC2=CC=CC=C2)O)O
  • InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1
  • Key:LOVMMUBRQUFEAH-UIEAZXIASA-N

Latanoprostene bunod, sold under the brand name Vyzulta, is an ophthalmic medication used for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension.[2][3] It is a prostaglandin analog[2] which, when broken down by esterases and other metabolism, produces latanoprost acid and eventually nitrous oxide. Latanoprost increases uveoscleral outflow while the nitrous oxide increases outflow via the trabecular meshwork.[3]

The most common side effects include conjunctival (eye) redness, eye irritation, and eye discomfort (pain).[4] Latanoprostene bunod may cause the iris (colored part of the eye) to become darker in color.[4]

Latanoprostene bunod was approved for medical use in the United States in November 2017.[2][4][5]

Medical uses

Latanoprostene bunod is indicated for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension.[2]

History

The US Food and Drug Administration (FDA) approved latanoprostene bunod based on evidence from two clinical trials that enrolled 840 participants with open angle glaucoma or ocular hypertension.[4] The trials evaluated the benefits and side effects of latanoprostene bunod.[4] In each trial, participants were randomly assigned to receive either latanoprostene bunod or an approved drug timolol (ophthalmic solution) every day for three months.[4] Neither the participants nor the health care providers knew which treatment was being given until after the trials were completed.[4] The trials were conducted in the United States, the United Kingdom, Germany, Italy, Bulgaria, the Czech Republic, and Japan.[4]

References

  1. ^ "Regulatory Decision Summary for Vyzulta". Health Canada. 27 December 2018.
  2. ^ a b c d e "Vyzulta- latanoprostene bunod solution/ drops". DailyMed. 1 May 2019. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
  3. ^ a b Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.
  4. ^ a b c d e f g h "Vyzulta". U.S. Food and Drug Administration (FDA). 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ "Bausch + Lomb And Nicox Announce FDA Approval Of Vyzulta (Latanoprostene Bunod Ophthalmic Solution), 0.024%" (Press release). Valeant Pharmaceuticals. 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024 – via PR Newswire.